IHC
Zymeworks, ALX Oncology Dose First HER2-Expressing Cancer Patient in Targeted Combo Trial
The companies are evaluating Zymeworks' bispecific antibody zanidatamab plus ALX's CD47-targeting agent evorpacept for HER2-expressing breast and other cancers.
Labcorp, CCORN Ink Partnership to Address Precision Oncology Disparities
The Community Clinical Oncology Research Network will leverage Labcorp's comprehensive genomic profiling test to build out a registry of diverse patient data.Â
Recent studies in NSCLC, melanoma, and breast cancer suggest that major histocompatibility complex expression could guide checkpoint inhibitor selection.
Researchers Look to Validate Promising Immunotherapy Response Biomarker in Early-Stage Breast Cancer
Premium
MHC-II expression could be useful for guiding neoadjuvant immunotherapy in HER2-negative breast cancers, according to findings in Clinical Cancer Research.
Bayer, OncoDNA, Tamkin Al-Seha Medical Partner to Offer NTRK Fusion Testing in Saudi Arabia
The partnership aims to test 1,000 advanced cancer patients in the country to determine their eligibility for the TRK inhibitor larotrectinib.